Compare DOMH & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMH | CSBR |
|---|---|---|
| Founded | 1967 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.3M | 83.5M |
| IPO Year | 2010 | 2015 |
| Metric | DOMH | CSBR |
|---|---|---|
| Price | $3.25 | $5.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 171.5K | 6.3K |
| Earning Date | 05-12-2026 | 03-12-2026 |
| Dividend Yield | ★ 23.45% | N/A |
| EPS Growth | 34.03 | ★ 161.11 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $123,104,000.00 | $2,900,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 578.41 | N/A |
| 52 Week Low | $2.69 | $5.50 |
| 52 Week High | $8.40 | $9.63 |
| Indicator | DOMH | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 51.07 | 47.98 |
| Support Level | $2.80 | $5.60 |
| Resistance Level | $3.45 | $6.31 |
| Average True Range (ATR) | 0.29 | 0.27 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 18.20 | 28.56 |
Dominari Holdings Inc is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management, and insurance. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce costs under a streamlined infrastructure. The Company operates in two reportable business segments: Dominari Financial and Legacy AIkido, with the majority of revenue from Dominari Financial.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.